Quick Answer
Dianthus Therapeutics, Inc. /DE/ reported Operating Income Loss of -$177.93 million for the year ending 2025.
- Dianthus Therapeutics, Inc. /DE/ showed a decrease of -74.7% in Operating Income Loss from 2024 to 2025.
- This data is from Dianthus Therapeutics, Inc. /DE/'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: -$4.81 million | Q2 2017: -$15.73 million | Q3 2017: -$7.02 million | Q4 2017: -$8.17 million | Q1 2018: -$11.31 million | Q2 2018: -$14.03 million | Q3 2018: -$16.70 million | Q4 2018: -$17.93 million | Q1 2019: -$16.35 million | Q2 2019: -$19.34 million | Q3 2019: -$22.64 million | Q4 2019: -$24.64 million | Q1 2020: -$21.24 million | Q2 2020: -$20.01 million | Q3 2020: -$18.38 million | Q1 2021: -$18.70 million | Q2 2021: -$17.61 million | Q3 2021: -$18.25 million | Q1 2022: -$23.83 million | Q2 2022: -$18.08 million | Q3 2022: -$8.25 million | Q1 2023: -$7.68 million | Q2 2023: -$11.78 million | Q3 2023: -$15.76 million | Q1 2024: -$17.84 million | Q2 2024: -$22.20 million | Q3 2024: -$29.90 million | Q1 2025: -$33.18 million | Q2 2025: -$34.93 million | Q3 2025: -$40.29 million.
- Over the full 10 years of available data (2016 to 2025), Dianthus Therapeutics, Inc. /DE/'s Operating Income Loss has declined by 1,819.9%.
- Historical annual values: Fiscal year 2025: -$177.93 million | Fiscal year 2024: -$101.86 million | Fiscal year 2023: -$48.17 million | Fiscal year 2022: -$29.71 million | Fiscal year 2021: -$74.69 million | Fiscal year 2020: -$78.70 million | Fiscal year 2019: -$82.97 million | Fiscal year 2018: -$59.96 million | Fiscal year 2017: -$35.73 million | Fiscal year 2016: -$9.27 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: